Braun Bostich & Associates Inc. Invests $350,000 in Merck & Co., Inc. (NYSE:MRK)

Braun Bostich & Associates Inc. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,206 shares of the company’s stock, valued at approximately $350,000.

A number of other large investors have also modified their holdings of the business. Perigon Wealth Management LLC boosted its position in Merck & Co., Inc. by 38.8% in the fourth quarter. Perigon Wealth Management LLC now owns 159,990 shares of the company’s stock valued at $17,442,000 after buying an additional 44,738 shares during the last quarter. Mosaic Family Wealth Partners LLC lifted its holdings in Merck & Co., Inc. by 4.0% in the fourth quarter. Mosaic Family Wealth Partners LLC now owns 2,995 shares of the company’s stock valued at $327,000 after acquiring an additional 116 shares during the period. MBE Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 2.9% in the fourth quarter. MBE Wealth Management LLC now owns 4,192 shares of the company’s stock valued at $457,000 after acquiring an additional 118 shares during the period. Kennedy Investment Group lifted its holdings in Merck & Co., Inc. by 16.0% in the fourth quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock valued at $280,000 after acquiring an additional 354 shares during the period. Finally, Sutton Place Investors LLC acquired a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $2,129,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.5 %

Shares of MRK traded down $0.62 during midday trading on Thursday, reaching $126.13. The company had a trading volume of 6,187,325 shares, compared to its average volume of 8,462,223. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10. The stock has a market cap of $319.44 billion, a PE ratio of 900.93, a price-to-earnings-growth ratio of 0.50 and a beta of 0.38. The firm has a 50 day simple moving average of $126.30 and a 200-day simple moving average of $114.02. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The business had revenue of $14.63 billion during the quarter, compared to the consensus estimate of $14.49 billion. During the same period last year, the company earned $1.62 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Research analysts forecast that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 5th. Investors of record on Friday, March 15th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date was Thursday, March 14th. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRK. Berenberg Bank boosted their price target on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday. Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Merck & Co., Inc. in a report on Friday, April 5th. Societe Generale downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a research note on Monday, March 11th. Finally, StockNews.com raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.64.

Read Our Latest Research Report on MRK

Insider Buying and Selling

In related news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the transaction, the executive vice president now directly owns 23,619 shares in the company, valued at approximately $2,991,346.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.